FDA grants Fast Track designation to Concert Pharmaceuticals’ CTP-543 for the treatment of alopecia aerata. Concert Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune…